It was previously believed that female carriers of X-linked inherited retinal diseases (IRDs) like X-linked retinitis pigmentosa (RP and Choroideremia) remained unaffected by sight loss.
News
The latest news from Retina UK. Please use the filters to find the articles which interest you.
Formal notice of the forthcoming Annual General Meeting in September 2024.
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
The collective partnership of eight of the leading charities in the sight loss sector, known for the last three years as the VI Charity Sector Partnership, has re-launched under a new identity of the ‘Vision Partnership’ with a re-invigorated purpose and new strategic focus.
CRISPR gene editing leads to improvements in vision for people with inherited blindness, clinical trial shows.
![Finlay Macleod - he is smiling directly at the camera and is wearing a light blue tshirt](https://retinauk.org.uk/wp-content/uploads/2023/10/Finlay-Square.png)
New Young Persons Project from Retina UK
We are proud to launch our new Young Persons Project, which will play a significant role in providing impactful and timely support for young people with inherited sight loss and mental health challenges, across the UK.
![](https://retinauk.org.uk/wp-content/uploads/2024/05/Logo-PNG.png)
New Gene Insertion Therapy for Stargard Disease in Development
SalioGen Developing Novel Gene Insertion Therapy for Stargardt disease.
![A hand with fingers crossed with the words 'Community Fund' alongside](https://retinauk.org.uk/wp-content/uploads/2024/04/digital-white-background.png)
Grant from The National Lottery Community Fund
We regularly make applications for grants to fund our information and support projects and have recently been successful in securing £12,000 from The National Lottery Community Fund.
![](https://retinauk.org.uk/wp-content/uploads/2024/04/OCGN-87ae5839.png)
Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).